- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04390126
COVID-19 Related Lockdown Effects On Chronic Diseases (CLEO-CD)
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term.
Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event.
The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring.
Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 21079
- Chu Dijon Bourgogne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with one of the following chronic diseases: chronic coronary syndrome, heart failure, multiple sclerosis, Horton's disease, AMD, malignant haemopathy, chronic respiratory failure (idiopathic fibrosis, PAH, haemophilia) and already registered in one of the 8 Burgundian registries/cohorts.
Exclusion Criteria:
- deceased patient, patient cannot be reached after >3 telephone calls, patient or caregiver does not speak French to carry out telephone interviews
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Register of haematological malignancies
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
Idiopathic Pulmonary Fibrosis and PAH Cohort
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
Giant Cell Arteritis Cohort
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
AMD and Macular Edema Cohort
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
Multiple Sclerosis Cohort
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
Myocardial Infarction Observatory RICO
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
Heart Failure Cohort
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
Hemophilia Cohort
|
Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
% adherence to each pharmacological class
Time Frame: during the period from 20 April 2020 to 7 May 2020
|
increase in dose, decrease in dose, discontinuation or no change for each drug class)
|
during the period from 20 April 2020 to 7 May 2020
|
number of occurrence of medical events at 1 year
Time Frame: throughout the study for 12 months
|
(mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)
|
throughout the study for 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expressed in %: Non-pharmacological treatment/lifestyle:
Time Frame: during the period from 20 April 2020 to 7 May 2020
|
Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change
|
during the period from 20 April 2020 to 7 May 2020
|
Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication
Time Frame: during the period from 20 April 2020 to 7 May 2020
|
during the period from 20 April 2020 to 7 May 2020
|
|
Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)
Time Frame: during the period from 20 April 2020 to 7 May 2020
|
during the period from 20 April 2020 to 7 May 2020
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Boulin M, Cransac-Miet A, Maynadie M, Volot F, Creuzot-Garcher C, Eicher JC, Chague F, Ksiazek E, Beltramo G, Bonniaud P, Moreau T, Bonnotte B, Sales-Wuillemin E, Soudry-Faure A, Zeller M, Cottin Y. COVID-19 Lockdown in Patients with Chronic Diseases: A Cross-Sectional Study. Int J Environ Res Public Health. 2022 Mar 26;19(7):3957. doi: 10.3390/ijerph19073957.
- Volot F, Soudry-Faure A, Callegarin A, Ksiazek E, Delienne S, Cottin Y, Maynadie M, Boulin M. Impact of first COVID-19 lockdown on paediatric and adult haemophilia patients treated in a French Haemophilia Comprehensive Care Centre. Haemophilia. 2022 May;28(3):462-471. doi: 10.1111/hae.14526. Epub 2022 Mar 3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Respiration Disorders
- Eye Diseases
- Disease Attributes
- Retinal Degeneration
- Retinal Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Vasculitis
- Skin Diseases, Vascular
- Macular Degeneration
- Vasculitis, Central Nervous System
- Arteritis
- Multiple Sclerosis
- Respiratory Insufficiency
- Macular Edema
- Chronic Disease
- Polymyalgia Rheumatica
- Giant Cell Arteritis
Other Study ID Numbers
- BOULIN AOIc 2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on life questionnaires
-
Centre Hospitalier Universitaire DijonCompletedIdiopathic Pulmonary Fibrosis | Patient-caregiver DyadsFrance
-
University Hospital, GrenobleUniversity Grenoble AlpsNot yet recruitingChildhood Cancer | Adapted Physical ActivityFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Asten SanteRecruiting
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Assistance Publique Hopitaux De MarseilleUnknownAtaxia | Hemiparesis | Paraparesis | Neuromuscular Disorders | Tetraparesis | Extrapyramidal Motor DisordersFrance
-
Ramsay Générale de SantéEuropean Clinical Trial Experts NetworkRecruiting
-
Columbia UniversityRecruitingBreast Cancer | Ductal Carcinoma in SituUnited States
-
Memorial Sloan Kettering Cancer CenterThe Cleveland ClinicCompletedQuality of Life | Prostate CancerUnited States
-
Centre Hospitalier Universitaire DijonCompletedPatients at Intensive Care UnitFrance